A dermatologic treatment for patients who have rosacea and other skin conditions increasingly will find use as an ophthalmologic treatment for patients who have dry eye as a result of meibomian gland dysfunction and blepharitis.
Patients being treated for glaucoma with bimatoprost ophthalmic solution 0.03% (Lumigan), who use the drug to reduce IOP, have been noticing a surprising side effect: longer and thicker eyelashes.
The hygiene hypothesis suggests that smaller family sizes as well as the use of antibiotics and vaccines has led to an allergy epidemic. Probiotics could reverse that epidemic and reduce the risk of developing atopic diseases and, potentially, nasal and ocular symptoms of respiratory allergies.
At month 24, 65.7% of patients treated with PDT, 90.0% of those treated with 0.3 mg ranibizumab, and 89.9% of those treated with 0.5 mg ranibizumab lost fewer than 15 letters compared with baseline. These results were very similar to the 12-month results.
Alexandria, Egypt—The debate over the efficacy of epi-LASIK and LASIK continues. Both procedures are safe, although the visual rehabilitation is slower in patients who undergo epi-LASIK. However, the visual results ultimately surpass those who had LASIK, according to Ahmed A. El-Massry, MD, who reported on a comparison study of the two procedures.
Las Vegas—Identification and pretreatment of allergy patients can improve refractive surgical outcomes, said Deepinder K. Dhaliwal, MD, at a continuing medical education symposium at the American Academy of Ophthalmology annual meeting. About 20% to 30% of refractive surgery patients have associated allergies, she added.
Milan, Italy—A comparison of custom and conventional LASIK ablations showed that both procedures provided very good results in terms of the uncorrected and best-corrected visual acuities (UCVA, BCVA) and refractive outcomes. Patients expressed greater quality of vision, however, with the results of the custom treatment, likely because of the better higher-order aberration values in that group, reported Luca Vigo, MD.
Santa Ana, CA—In a move designed to boost its quest for the "custom all-laser LASIK," Advanced Medical Optics (AMO) has acquired WaveFront Sciences, Albuquerque, NM, for about $20 million.
Las Vegas—Marcelo V. Netto, MD, was presented with the 16th annual Troutman Award at the annual meeting of the American Academy of Ophthalmology. He received the award as lead author of a paper that described the findings from wavefront analysis in a population of normal refractive surgery patients [Netto MV, et al. J Refract Surg. 2005;21:332-338].
The acquisition of IntraLase Corp. by Advanced Medical Optics (AMO), announced Jan. 9, joins two of the strongest performers in the refractive surgery market. The $808 million cash transaction may be the impetus for a change in how the traditional microkeratome is viewed among refractive surgeons.